Potential Therapeutic Features of Human Amniotic Mesenchymal Stem Cells in Multiple Sclerosis: Immunomodulation, Inflammation Suppression, Angiogenesis Promotion, Oxidative Stress Inhibition, Neurogenesis Induction, MMPs Regulation, and Remyelination Stimulation.
Amnion
Cell Differentiation
/ physiology
Endothelial Cells
/ immunology
Humans
Immunomodulation
/ immunology
Inflammation
/ immunology
Matrix Metalloproteinases
/ metabolism
Mesenchymal Stem Cell Transplantation
/ methods
Mesenchymal Stem Cells
/ cytology
Microglia
/ immunology
Multiple Sclerosis
/ immunology
Neovascularization, Pathologic
/ pathology
Neurogenesis
/ immunology
Neurons
/ immunology
Oxidative Stress
/ physiology
Remyelination
/ physiology
amniotic membrane
angiogenesis
anti-inflammation
antioxidant
mesenchymal stem cell
multiple sclerosis
neurogenesis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
10
2018
accepted:
28
01
2019
entrez:
8
3
2019
pubmed:
8
3
2019
medline:
22
7
2020
Statut:
epublish
Résumé
Multiple sclerosis (MS) is an inflammatory and degenerative disorder of the central nervous system with unknown etiology. It is accompanied by demyelination of the nerves during immunological processes in the presence of oxidative stress, hypoxia, cerebral hypo-perfusion, and dysregulation in matrix metalloproteinases (MMPs). Human amniotic mesenchymal stem cells (hAMSCs) as pluripotent stem cells possess some conspicuous features which could be of therapeutic value in MS therapy. hAMSCs could mimic the cascade of signals and secrete factors needed for promoting formation of stable neovasculature and angiogenesis. hAMSCs also have immunomodulatory and immunosuppressive effects on inflammatory processes and reduce the activity of inflammatory cells, migration of microglia and inhibit recruitment of certain immune cells to injury sites. hAMSCs attenuate the oxidative stress supported by the increased level of antioxidant enzymes and the decreased level of lipid peroxidation products. Furthermore, hAMSCs enhance neuroprotection and neurogenesis in brain injuries by inhibition of inflammation and promotion of neurogenesis. hAMSCs could significantly increase the expression of neurotrophic factors, which prevents neurons from initiating programmed cell death and improves survival, development, and function of neurons. In addition, they induce differentiation of neural progenitor cells to neurons. hAMSCs could also inhibit MMPs dysregulation and consequently promote the survival of endothelial cells, angiogenesis and the stabilization of vascular networks. Considering the mentioned evidences, we hypothesized here that hAMSCs and their conditioned medium could be of therapeutic value in MS therapy due to their unique properties, including immunomodulation and inflammation suppression; angiogenesis promotion; oxidative stress inhibition; neurogenesis induction and neuroprotection; matrix metalloproteinases regulation; and remyelination stimulation.
Identifiants
pubmed: 30842772
doi: 10.3389/fimmu.2019.00238
pmc: PMC6391358
doi:
Substances chimiques
Matrix Metalloproteinases
EC 3.4.24.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
238Références
J Neurol. 2004 Mar;251(3):261-8
pubmed: 15015004
J Clin Neurosci. 2004 Sep;11(7):689-92
pubmed: 15337125
Curr Alzheimer Res. 2006 Feb;3(1):19-24
pubmed: 16472198
Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29;361(1473):1545-64
pubmed: 16939974
J Neurosci. 2006 Dec 13;26(50):12904-13
pubmed: 17167081
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7558-63
pubmed: 17463082
Eur Cell Mater. 2008 Apr 29;15:88-99
pubmed: 18446690
J Autoimmun. 2008 Nov;31(3):288-94
pubmed: 18504116
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Nat Rev Drug Discov. 2008 Nov;7(11):909-25
pubmed: 18974749
J Neurochem. 2009 Sep;110(5):1674-84
pubmed: 19619133
PLoS One. 2010 Feb 02;5(2):e9016
pubmed: 20126406
Mult Scler. 2010 May;16(5):537-48
pubmed: 20194580
Biochim Biophys Acta. 2011 Feb;1812(2):141-50
pubmed: 20600869
J Cell Physiol. 2011 Feb;226(2):385-96
pubmed: 20665704
Nat Rev Immunol. 2010 Oct;10(10):712-23
pubmed: 20865019
Neurochem Res. 2011 Feb;36(2):268-80
pubmed: 21080066
Cytotherapy. 2011 May;13(5):572-81
pubmed: 21208022
Cell Biol Int. 2011 Dec;35(12):1247-51
pubmed: 21649586
Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17384-9
pubmed: 21960443
Trends Immunol. 2012 Mar;33(3):136-43
pubmed: 22227317
Curr Neuropharmacol. 2011 Sep;9(3):409-16
pubmed: 22379455
J Vet Sci. 2012 Mar;13(1):23-31
pubmed: 22437532
Eur J Pharmacol. 2012 Jul 5;686(1-3):124-9
pubmed: 22575526
Int J Mol Sci. 2012;13(7):9298-331
pubmed: 22942767
Stem Cells Int. 2012;2012:721538
pubmed: 23093978
Biol Res. 2012;45(3):257-68
pubmed: 23283435
Placenta. 2013 Apr;34(4):340-5
pubmed: 23465536
Neurobiol Aging. 2013 Oct;34(10):2408-20
pubmed: 23623603
J Biol Chem. 2013 Jun 21;288(25):18533-45
pubmed: 23653362
Front Physiol. 2013 Jul 25;4:169
pubmed: 23898299
PLoS One. 2013 Jul 26;8(7):e69795
pubmed: 23922802
Stem Cells Int. 2013;2013:435093
pubmed: 23997771
Clin Dev Immunol. 2013;2013:708659
pubmed: 24174971
Am J Transl Res. 2014 Jan 15;6(2):119-28
pubmed: 24489991
BMB Rep. 2014 Mar;47(3):135-40
pubmed: 24499672
Brain Res. 2014 Nov 24;1590:1-9
pubmed: 24909791
Front Neurosci. 2014 Jun 12;8:145
pubmed: 24971048
Acta Neuropathol Commun. 2014 Aug 27;2:97
pubmed: 25159125
World J Exp Med. 2014 Aug 20;4(3):27-37
pubmed: 25254187
J Mol Histol. 2015 Feb;46(1):13-20
pubmed: 25432786
Stem Cells Transl Med. 2015 Mar;4(3):239-51
pubmed: 25646527
J Neuroinflammation. 2015 Jun 03;12:112
pubmed: 26036872
PLoS One. 2015 Sep 25;10(9):e0139008
pubmed: 26407166
Cryobiology. 2015 Dec;71(3):413-8
pubmed: 26432457
Biomed Res Int. 2015;2015:324014
pubmed: 26491665
Exp Neurol. 2016 Mar;277:58-67
pubmed: 26626971
Trends Neurosci. 2016 Apr;39(4):246-263
pubmed: 26964504
Biochem Biophys Res Commun. 2016 Jun 24;475(2):202-8
pubmed: 27188654
J Tissue Eng Regen Med. 2017 Oct;11(10):2895-2911
pubmed: 27396853
Oncol Lett. 2016 Sep;12(3):1877-1883
pubmed: 27588134
Microcirculation. 2017 Jan;24(1):
pubmed: 27681821
Cell Tissue Bank. 2017 Mar;18(1):1-15
pubmed: 27830445
Sci Transl Med. 2016 Nov 9;8(364):364ra152
pubmed: 27831901
Am J Transl Res. 2017 Mar 15;9(3):940-952
pubmed: 28386323
CNS Drugs. 2017 Jun;31(6):453-469
pubmed: 28397112
Cytotherapy. 2017 Aug;19(8):990-1001
pubmed: 28566211
J Neuroinflammation. 2017 Jun 9;14(1):117
pubmed: 28599652
Ann Neurol. 2017 Aug;82(2):186-195
pubmed: 28681388
J Obstet Gynaecol Res. 2017 Nov;43(11):1758-1768
pubmed: 28707770
Lancet Neurol. 2017 Oct;16(10):764-766
pubmed: 28920874
Biochem Biophys Rep. 2016 Aug 03;8:34-40
pubmed: 28955939
Sci Rep. 2017 Sep 29;7(1):12426
pubmed: 28963485
Brain. 2017 Nov 1;140(11):2776-2796
pubmed: 29053779
Cell Physiol Biochem. 2017;44(4):1360-1369
pubmed: 29186705
Sci Rep. 2017 Dec 5;7(1):17022
pubmed: 29208979
Sci Rep. 2017 Dec 21;7(1):18019
pubmed: 29269885
BMB Rep. 2018 Apr;51(4):194-199
pubmed: 29429450
Cell Transplant. 2018 Jan;27(1):31-44
pubmed: 29562786
Biomark Insights. 2018 May 18;13:1177271918774800
pubmed: 29795976
Mol Neurobiol. 2019 Feb;56(2):954-962
pubmed: 29808380
Stem Cells Int. 2018 Jun 14;2018:3057624
pubmed: 30013600
J Immunol Res. 2018 Jun 24;2018:5083797
pubmed: 30035132